BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201022
DTSTAMP:20260515T044308
CREATED:20200803T090036Z
LAST-MODIFIED:20200813T133334Z
UID:26605-1603065600-1603324799@www.pharmajournalist.com
SUMMARY:5th Microbiome Movement – Drug Development Summit
DESCRIPTION:The 5th Microbiome Movement – Drug Development Summit (October 19-21\, Digital Event – EDT) continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical\, biotech and academic community pursue the causal role of the human microbiome in disease\, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs. \n \nWith over 60 speakers taking part\, the four focus areas for 2020 include: \n\nPre-Clinical Development & Mechanisms of Microbiome-based Therapeutics\nLearn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes\nClinical Development\, Manufacturing & Commercialization of Live Biotherapeutics\nAs the industry prepares for pivotal clinical readouts this summer\, this year’s discussion will give you the knowledge and insight required to navigate through the specific translational\, clinical and manufacturing challenges for live biotherapeutics\nMicrobiome-based Biomarkers\, Diagnostics & Patient Stratification\nMine the human microbiome to discover new biomarkers of disease and help predict response\, understand drug metabolism and develop non-invasive diagnostic tools\nApplications in Oncology\nGain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers\, oncology-specific clinicians and the pharmaceutical industry\n\nIf you are\, or would like to be\, a player in the microbiome arena\, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics\, biomarkers and diagnostics\, but also to make long-lasting connections that will accelerate your microbiome developments forward\, and help translate this promising science into a reality for patients.
URL:https://www.pharmajournalist.com/event/5th-microbiome-movement-drug-development-summit/
LOCATION:Digital Event – EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201020
DTEND;VALUE=DATE:20201022
DTSTAMP:20260515T044308
CREATED:20200910T130153Z
LAST-MODIFIED:20200917T151939Z
UID:26975-1603152000-1603324799@www.pharmajournalist.com
SUMMARY:Outsourcing in Clinical Trials Nordics 2020
DESCRIPTION:After the challenges of 2020 with the Covid-19 pandemic\, this is the unmissable event that the pharmaceutical\,\nbiotechnology\, and medical device communities need to come together and discuss strategies for operational success in clinical trials. With all the latest content\, and a big focus on the latest regulations and technology\, the conference will offer an unparalleled opportunity to hear in-depth talks from the likes of the Danish Medicines Agency\, LEO Pharma\, and TÜV SÜD\, as well as C-level and senior experts from the Nordic region. \n\nTo know more about Outsourcing in Clinical Trials Nordics 2020 please click here.
URL:https://www.pharmajournalist.com/event/outsourcing-in-clinical-trials-nordics-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T044308
CREATED:20181206T115237Z
LAST-MODIFIED:20200320T123611Z
UID:18694-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes East Coast 2020
DESCRIPTION:SMi are proud to announce the 7th annual conference: \nPre-Filled Syringes East Coast 2020\n26-27 October 2020\nBoston\, USA\nSheraton Boston Hotel\nhttp://www.pfsamericas.com/pjwl \nInnovations in parenteral device and product development \n \nSMi Group are proud to announce the 7th Pre-Filled Syringes East Coast conference returning to Boston\, USA on 26th-27th October 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, for its 7th year running- the 2020 event will aim to focus on new trends on digital technology advancements\, human studies and innovative design and delivery systems within the prefilled syringe industry. \nThemes for 2020: \nPre-Filled Syringes East Coast 2020 will be exploring themes of Container Closure Interaction and Formulation; On-body Injectors; Digital connectivity in the parenteral space; A regulatory outlook with industry and recognised body experts; Patient centricity and device development; Developments in device technology; Parenteral gene therapy and New for 2020: PFS Interactive Workshop Day. \nThis comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more.. \nKey Reasons to Attend: \n\nEXPLORE the latest case studies parenteral drug delivery\nGAIN insights into the use of pre-filled syringes for gene therapy\nNETWORK with leading industry experts\, key opinion leaders and regulatory body representatives\nENGAGE in the key challenges and topics of the field in the interactive post-conference workshop day\n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nTo register or for more information visit: www.pfsamericas.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/prefilled-syringes-east-coast/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="SMi Group Ltd":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T044308
CREATED:20191215T134154Z
LAST-MODIFIED:20200813T143407Z
UID:23372-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:Smithers’ Extractables and Leachables USA 2020
DESCRIPTION:Smithers’ 9th annual Extractables and Leachables USA conference is returning. This is a unique event in the extractables and leachables industry\, bringing together top companies from the entire supply chain and making it easy to network with peers\, leading to new\, beneficial connections. The event is a must for the extractables and leachables industry\, wherein players need to stay on top of market changes\, fluctuating regulations\, medical device strategies\, and safety standards for consumer safety and product success. Smithers’ E&L 2020 gathers industry experts to discuss these topics\, and more. The program consists of two days of industry-leading presentations by over 20 expert speakers\, supplemented by valuable networking breaks\, an included networking lunch\, and a networking reception at the end of day one. \nCompanies who have attended in the past include B Braun\, The FDA\, Toxikon\, Intertek\, Abbott\, Nelson Laboratories\, Boston Scientific\, Vimta\, Jordi Labs\, VR Analytical\, Teknor Apex\, and many more. \nVisit the event website for more information: https://www.eandl-conference.com/usa. \nContact Producer Ashli Speed\, ASpeed@Smithers.com\, with questions about the program. \nFor companies interested in increasing their brand visibility in front of a target market\, contact Shannon Siegferth\, SSiegferth@Smithers.com\, about sponsorship opportunities. \nTo get the latest updates\, follow the event on twitter @SmithersELEvent\, join the LinkedIn group Extractables and Leachables Forum\, or join the mailing list: https://www.eandl-conference.com/usa/register-interest.
URL:https://www.pharmajournalist.com/event/extractables-and-leachables-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Smithers":MAILTO:sheitzenrater@smithers.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T044308
CREATED:20200806T100433Z
LAST-MODIFIED:20200806T100433Z
UID:26627-1603670400-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Summit
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Summit will gather the greatest minds in TIGIT research in a dedicated\, two day meeting. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings for your future research. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a meeting that brings together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, this event will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Summit website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201029
DTSTAMP:20260515T044308
CREATED:20200817T085404Z
LAST-MODIFIED:20200817T085404Z
UID:26772-1603670400-1603929599@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders Europe | Running Digitally for 2020
DESCRIPTION:Realise the Commercial Potential of Gene Therapies \nThe 4th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming\nmanufacturing\, clinical\, and commercialisation challenges drug developers face when delivering\ngene therapies to market. \nWith new European gene therapy approvals rapidly approaching and investment at an all-time high\, the digital meeting will leverage the experience from the first to market pioneers\, as well as unveiling the strategies the next generation of drug developers are employing to improve efficacy\, safety and commercial viability. \n \nAcross three days\, we will virtually unite 250+ leading experts from innovative biotechs\, large pharmaceutical companies\, academia\, and key service providers. Understand the nuances of the European regulatory landscape\, engage with European payers and ensure your manufacturing and logistical approaches are set for the commercial primetime to come. \nWherever you’re based\, if you’re looking to develop and launch gene therapy products in Europe\, this is your comprehensive guide to define your commercial path forward \nTo learn more about Gene Therapy for Rare Disorders Europe please click here: https://ter.li/k19u77
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders-europe-running-digitally-for-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20260515T044308
CREATED:20200716T134602Z
LAST-MODIFIED:20200716T135026Z
UID:26349-1603756800-1603843199@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-2/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T044308
CREATED:20200722T112338Z
LAST-MODIFIED:20200722T112338Z
UID:26438-1603756800-1604015999@www.pharmajournalist.com
SUMMARY:Macrophage-directed Therapies Summit 2020
DESCRIPTION:Harnessing the Potential of Macrophage Therapies Using Small Molecule\, Antibody & Cell Therapy based Approaches for Oncology and Beyond \nWith the explosive excitement and clinical proof of concepts utilizing CD47 approaches\, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47. \n \nThe 2nd Macrophage-directed Therapies Summit is focused on optimizing the potential of macrophage therapies\, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond. \nBringing together the leading experts\, we will explore the clinical development of CD47 checkpoint blockades\, combination strategies\, macrophage repolarization approaches and engineered macrophages. \nJoin the trailblazers of macrophage therapeutic development\, from the likes of Carisma Therapeutics\, Faron Pharmaceuticals\, and Verseau Therapeutic\, as we come together to advance the fundamental understanding of macrophage biology\, avoiding on-target toxicities and the emerging field of macrophage cellular immunotherapy.
URL:https://www.pharmajournalist.com/event/macrophage-directed-therapies-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T044308
CREATED:20171009T143124Z
LAST-MODIFIED:20200810T095904Z
UID:3348-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Pharmaceutical Microbiology East Coast
DESCRIPTION:SMi’s 3rd Annual Pharmaceutical Microbiology East Coast\nConference: 28 – 29 October 2020\nLocation: Virtual Event\nWebsite: www.microbiologyeastcoast.com/PJWL \nSPONSORED BY: Associates of Cape Cod\, bioMérieux\, Bioscience International\, C.T.L. MAT\, LONZA \nCHAIRED BY: Lynne Ensor\,VP Technical\, Parexel \nExploring the current approaches towards improved contamination control \nThe pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods\, revisions being made to regulations in the industry\, enhanced knowledge of the human microbiome\, and novel testing methods\, this industry is ever expanding. \nJoin industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals\, discuss the revision of Annex 1\, explore data integrity considerations for conventional and rapid microbiology methods\, analyze arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation. \nEvent Hashtag: #SMiPharmaMicroEC \nHIGHLIGHTS FOR 2020: \n\nDiscuss ongoing complication of personnel derived contaminations from the FDA\nGain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel\nLearn from the perspective of the US Pharmacopeia on container closure integrity evaluation\nExamine an end-to-end contamination risk assessment for autologous cell therapy from Juno Therapeutics\nExplore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past\, current and future state of Mycoplasma testing\n\nThe Use of Recombinant Chromogenic Assays as Alternate Methods for the Bacterial Endotoxins Test (BET) \nWorkshop Leader:\nVeronika Wills\, Manager\, Technical Services\, Associates of Cape Cod \nView the full agenda: www.microbiologyeastcoast.com/PJWL \nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nTo know more about Pharmaceutical Microbiology East Coast please click here.
URL:https://www.pharmajournalist.com/event/pharmaceutical-microbiology-east-coast/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201028
DTEND;VALUE=DATE:20201030
DTSTAMP:20260515T044308
CREATED:20200812T084028Z
LAST-MODIFIED:20200812T084028Z
UID:26683-1603843200-1604015999@www.pharmajournalist.com
SUMMARY:Dry AMD Therapeutic Development Summit
DESCRIPTION:Finding new therapeutics to counter the progression of Dry AMD and prevent the geographical atrophy has never been more important. The aging population creates an ever-growing clinical need for next-generation therapeutics. \nThis action-packed two-day digital agenda holds 22 Presentations from industry and academic leaders\, a virtual poster session and 5+ hours of networking\, you can join the only platform discussing issues present in the development of Dry AMD therapeutics. \n \nJoin this critical global forum which will be uniting industry specialists from pharma\, biotechs\, academia and solution providers as we target the most pressing issues important to bringing the next generation of Dry AMD drugs to market. \nCompanies speaking include: Genentech\, 4D Molecular Therapeutics\, Alkeus Pharmaceuticals\, Inc.\, Boehringer Ingelheim International GmbH\, University of California\, San Francisco\, Regenerative Patch Technologies\, Novartis\, Stealth BioTherapeutics Inc \nFind out more here > https://ter.li/mc1pmz
URL:https://www.pharmajournalist.com/event/dry-amd-therapeutic-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201029
DTEND;VALUE=DATE:20201031
DTSTAMP:20260515T044308
CREATED:20200709T091800Z
LAST-MODIFIED:20200709T092312Z
UID:26239-1603929600-1604102399@www.pharmajournalist.com
SUMMARY:Patient-to-Patient Supply for Cell Immunotherapies Summit
DESCRIPTION:Achieving Standardization & Operational Excellence in Vein-to-Vein Supply \nAs an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment\, cell therapies pose unique supply chain challenges. \n \nAt the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit\, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nFrom time and temperature sensitivity\, to patient-facing service and integrated platforms\, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience. \nJoin the strategic experts from GSK\, bluebird bio\, Adaptimmune\, Celgene\, BMS and more\, to discuss best practice for patient-facing supply chains and build integrated platforms for chain of identity and end-user access.
URL:https://www.pharmajournalist.com/event/patient-to-patient-supply-for-cell-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201103
DTEND;VALUE=DATE:20201106
DTSTAMP:20260515T044308
CREATED:20200803T075703Z
LAST-MODIFIED:20200803T094758Z
UID:26593-1604361600-1604620799@www.pharmajournalist.com
SUMMARY:Digital 5th Neoantigen Based Therapies Summit
DESCRIPTION:With all eyes on the explosive neoantigen field watching to see how it can revolutionize cancer immunotherapies and rival the current T cell therapies\, it is clear that critical questions still remain to be addressed to ensure full therapeutic success. \n \nTaking place from the comfort of your own home this year\, the 5th Neoantigen Based Therapies Summit remains the only industry focused meeting dedicated to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies. \nView the full event guide for more details on this content packed 3-day virtual event. \nWe’ll be addressing the most pressing challenges in the field\, including: \n\nIdentifying both personalized and shared Neoantigens to supercharge development of next generation immunotherapy with University of Miami and Netherlands Cancer Institute\nImproving prediction accuracy by exploring different neoantigen sources with Ervaxx\, Precision Biologics and Broad Institute\nHow to maximize immunogenicity to drive clinical development & success with Gritstone Oncology\, Genocea and Treos Bio\nReducing complex process and release times by navigating through complex manufacturing challenges with Achilles Therapeutics\, Vaximm and ISA Therapeutics\n\nDownload the official brochure to see what sessions will help you to advance your cancer immunotherapy pipeline. \nJoin us online to gain the practical insights you need to improve the immune response and commercial viability of your neoantigen based cancer immunotherapy.
URL:https://www.pharmajournalist.com/event/digital-5th-neoantigen-based-therapies-summit/
LOCATION:Online | Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T044308
CREATED:20200422T104308Z
LAST-MODIFIED:20200605T111205Z
UID:25191-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:8th Microbiome R&D & Business Collaboration Forum: USA
DESCRIPTION:This forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \n \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/8th-microbiome-rd-business-collaboration-forum-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T044308
CREATED:20200422T105422Z
LAST-MODIFIED:20200605T110713Z
UID:25195-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:2nd Skin Microbiome & Cosmeceuticals Congress: USA
DESCRIPTION:This congress will explore the burgeoning field of skin microbiome research\, with case studies focused on topics such atopic dermatitis\, psoriasis\, acne\, and allergy\, and the microbiome-based products being developed to fight these diseases. The conference also provided insight into the future of microbiome-based cosmetics\, with numerous presentations given on trial design\, commercial strategy\, and consumer awareness and expectations. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/2nd-skin-microbiome-cosmeceuticals-congress-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201105
DTEND;VALUE=DATE:20201107
DTSTAMP:20260515T044308
CREATED:20200422T133821Z
LAST-MODIFIED:20200605T111031Z
UID:25202-1604534400-1604707199@www.pharmajournalist.com
SUMMARY:5th Probiotics & Prebiotics Congress: USA
DESCRIPTION:This Congress will include numerous presentations on probiotics discovery and product development\, as well as prebiotics\, diet and nutrition. Alongside several case studies on digestive health\, metabolic diseases\, ageing and allergy\, the conference highlighted the importance of the early life microbiome\, the milk microbiome\, and the use of probiotics to modulate the infant gut. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda. \n 
URL:https://www.pharmajournalist.com/event/5th-probiotics-prebiotics-congress-usa/
LOCATION:San Diego\, USA
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T044308
CREATED:20200722T114844Z
LAST-MODIFIED:20200722T114844Z
UID:26443-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:3rd Annual Lab Asset & Facility Management in Pharma 2020
DESCRIPTION:The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM\, enabling you to regain control of your assets\, optimize your space and benchmark best practices to stay ahead of the curve. \n \nThrough strategic planning and rolling out digital tracking\, Lab Asset\, Operations and FM Directors are beginning to regain control of their inventory\, asset value and optimize facility footprint to: \n\nReduce unnecessary downtime and ensure reliable business operations\nStrengthen relationships and drive innovative partnership models with OEMs\nMaximize asset lifecycle and value – and make informed financial decisions during purchasing\, renewing\, reselling and auctioning\nOptimize lab and working space\, implementing the ethos of shared economy within the R&D scientific community\nEnhance capital efficiency to re-invest in drug development programs\nAnticipate expansion from a lab and equipment perspective
URL:https://www.pharmajournalist.com/event/3rd-annual-lab-asset-facility-management-in-pharma-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T044308
CREATED:20200727T160850Z
LAST-MODIFIED:20200727T160850Z
UID:26517-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:Digital Neuropsychiatric Drug Development Summit
DESCRIPTION:The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive\, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics. \n \nWith an emphasis on depressive disorders\, schizophrenia\, addiction and PTSD\, this timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nDive into novel therapeutic approaches for PTSD with Aptinyx\, Bionomics\, Tonix & MAPS\nUncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics\, NeuroRx & Intra-cellular Therapeutics\nExplore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis\, Otsuka & Yale University\nHear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA\nLearn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern\n\nUniting 60+ drug developers from all corners of the world\, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics. \nTo know more about Digital Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/digital-neuropsychiatric-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201114
DTSTAMP:20260515T044308
CREATED:20200818T085642Z
LAST-MODIFIED:20200818T090545Z
UID:26793-1604966400-1605311999@www.pharmajournalist.com
SUMMARY:TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:Europe’s #1 forum for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market\, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies\, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition\, and work towards collaborations.
URL:https://www.pharmajournalist.com/event/tides-europe-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201111
DTSTAMP:20260515T044308
CREATED:20200821T150457Z
LAST-MODIFIED:20200821T150457Z
UID:26819-1604966400-1605052799@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Rare Non-Oncological Disorders
DESCRIPTION:The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma\, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/ \nTackling critical challenges from early research through to late-stage market access\, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need. \n How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products? \n Drawing on a multitude of disease areas spanning neurology\, cardiology\, metabolic\, renal\, inflammatory and more\, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities. \nWith 2 days of in-depth case studies\, interactive panel discussions\, dedicated Q+A time and valuable networking opportunities\, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory\, payer and commercial discussions. \nTake a look at the full event guide to see all case studies\, pre-conference workshop details and the full expert speaker faculty!
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-rare-non-oncological-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201112
DTSTAMP:20260515T044308
CREATED:20201109T092141Z
LAST-MODIFIED:20201109T092440Z
UID:27850-1604966400-1605139199@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin 2020
DESCRIPTION:2019 proved to be a pivotal year for the skin microbiome\, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly\, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations. \n \nMoving forward into 2021\, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis\, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products. \nSo\, what’s different at Microbiome Connect: Skin EU Virtual? \nSix new topics to explore: \n\nThe skin-gut axis and the development of ingestible beauty products.\nPersonalisation of skin-microbiome products and formulation considerations.\nDefining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.\nNext generation sequencing techniques and their application in claims development.\nNew data demonstrating the role of the microbiome in common skin conditions including acne\, eczema and dandruff.\nThe vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.\n\nAll tickets to tune into this event are 2FOR1 – simply quote this when booking online!
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201111
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T044308
CREATED:20200908T143929Z
LAST-MODIFIED:20200908T143929Z
UID:26962-1605052800-1605225599@www.pharmajournalist.com
SUMMARY:2nd Digital Exosome Based Therapeutic Development Summit
DESCRIPTION:The exosome therapeutics field is booming with anticipation as preparations are underway for the first few clinical trials and money pours in through partnerships and pipeline acquisitions. However\, more is needed to be done to uncover more scientific knowledge\, fine-tune manufacturing methods and prepare trials to meet regulatory expectations. \nConsidering this\, the 2nd Digital Exosome Based Therapeutic Development Summit (November 11-12\, 2020) will unite pharma\, biotech\, academic and technology providers to advance exosome therapeutics into a clinical and commercial reality. \n \nThis is your only industry-focused meeting dedicated specifically to evidence-based and regulated exosome-based therapeutics. Bringing together industry leaders and newcomers on the field\, it’s two days not to be missed. \nWith 20+ speakers and 2 days of unrivalled in-depth content\, join your peers to discuss: \n\nEnd-to-end insights on drug development from discovery to scalable manufacturing of GMP-grade exosomes\, clinical preparation\, commercial strategy and more with Evox Therapeutics\, Aruna Bio\, Codiak Biosciences and ReNeuron\nInnovations in exosome-based therapeutics\, such as their applications in COVID-19 vaccines with Capricor Therapeutics\nUnderstanding the underlying mechanisms of exosome interactions to inform target identification and development decisions with Scripps Research and University Hospital Essen\nPreparing for clinical trials with key lessons learned from the best in the business such as Aegle Therapeutics\nOver 4+ hours scheduled virtual networking time to connect with the community all from the comfort of your own home or office!\n\nIf you are exploring the therapeutic applications of exosomes in an evidence-based approach\, this is the place for you. \nSpanning 2 days\, this digital program is tailor-made to showcase the field’s most exciting breakthroughs to inform your discovery\, manufacturing\, commercial and regulatory strategies. Join this interactive forum this November to drive GMP-grade manufacturing methods\, consistent exosome production\, improved isolation and purification\, effective clinical and regulatory preparations\, beneficial industry partnerships and more. \nTo know more about 2nd Digital Exosome Based Therapeutic Development Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-digital-exosome-based-therapeutic-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201112
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T044308
CREATED:20201109T093155Z
LAST-MODIFIED:20201109T093155Z
UID:27859-1605139200-1605225599@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Human 2020
DESCRIPTION:Microbiome Connect: Human EU has been postponed this year due to the impacts of COVID-19.  However\, at Microbiome Connect\, we’re committed to continue providing a platform for scientific presentations and networking opportunities for the microbiome community before we return to face-to-face again in 2021. \n \nThis November\, we’ll be running a free-to-attend virtual symposium highlighting some of the latest scientific activity. Tune in for free on 12th November\, 2020. \nAgenda: \n9.30 – 10:00 AM | Iron and the gut microbiome: an opportunity for LBPs functional during active gut inflammation\nJenny Bailey – CEO – Ferryx \n10.15 – 10:40 AM | Gut-Brain axis mechanism of action and Clinical results on Hafnia alvei HA4597\, a new probiotic strain for the regulation of appetite and weight management\nGregory Lambert – CEO – Targedys \n10:55 – 11:20 AM | Rationally Designed Probiotic\nDr. Olaf Larsen – Senior Manager Science – Yakult Nederland B.V. \nRegister for free online.
URL:https://www.pharmajournalist.com/event/microbiome-connect-human-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T044308
CREATED:20200422T134911Z
LAST-MODIFIED:20200422T134911Z
UID:25203-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:4th Global Pharma R&D AI\, Data Science and Informatics Summit
DESCRIPTION:This Summit is designed to create a collaborative environment in which attendees engaged with the speakers\, sponsors and other delegates in attendance. The meeting agenda has expanded to include: \n\nAI for genomics\, single-cell analysis and target validation.\nAI for predicting patient response.\nAI impacting clinical trials.\nAI for imaging.\nAI for cancer immunotherapy and neurodegenerative diseases\,\nClinical informatics\, data integration\, management and storage\,\nDigital therapeutics\, wearables and sensors.\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/4th-global-pharma-rd-ai-data-science-and-informatics-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201118
DTSTAMP:20260515T044308
CREATED:20200423T105853Z
LAST-MODIFIED:20200423T105853Z
UID:25211-1605484800-1605657599@www.pharmajournalist.com
SUMMARY:5th Medicinal Chemistry & Protein Degradation Summit
DESCRIPTION:This Summit will focus its attention to some of the leading issues in Medicinal Chemistry today. This year the conference has expanded its coverage on protein degradation and will have a dedicated track running across both days to explore the cutting-edge research taking place in this exciting area.  \nThe integration of AI and machine learning into the medicinal chemistry process is tackled in another track at the meeting with numerous case studies into how this developing technology is being utilized by industry leaders including Exscientia\, Insitro and Bayer. This compliments the co-located informatics and AI meeting\, which can be attended at any time\, and examines artificial Intelligence in other parts of the drug discovery timeline. \nFinally\, the conference will be looking into recent advances and case studies in phenotypic screening and novel approaches to DNA encoded libraries within a dedicated track. \nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships.  \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/5th-medicinal-chemistry-protein-degradation-summit/
LOCATION:London\, UK
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T044308
CREATED:20200826T130619Z
LAST-MODIFIED:20200826T130619Z
UID:26852-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:2nd Annual Proteome- Targeted Drug Discovery Summit – Digital Event
DESCRIPTION:With about 85% of the proteome currently undrugged\, accessing these targets that are\, at present\, extremely difficult to drug\, has prevented researchers from achieving desired clinical successes. \nThe 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech\, as well as key opinion leaders in academia\, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency\, selectivity\, and physio-chemical properties. \n \nJoin the leading experts from the biopharmaceutical industry and academia to enhance your existing structural\, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline. \nKey Reasons to Attend Include \n\nUtilize next-generation chemical biology platforms for novel target target identification with insights from Biogen\, Merck & AstraZeneca\nExpand the druggable proteome through next-generation screening platforms\, with insight from GSK\, PhoreMost & Ribon Therapeutics\nLeverage innovative chemical probes to accelerate fragment-based lead generation\, with insights from Novartis & The Weizmann Institute of Science\nHarness structure-based computational technologies to successfully target protein-protein interactions\, with insights from RAPT Therapeutics\nGive rise to novel therapeutic modalities to drug the undruggable\, with insights from Silicon Therapeutics& AbbVie\n\nTo know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-proteome-targeted-drug-discovery-summit-digital-event/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T044308
CREATED:20200917T132624Z
LAST-MODIFIED:20200917T132919Z
UID:27122-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:4th Annual Antifibrotic Drug Development Summit
DESCRIPTION:Solving the Translational Drug Development Gap\, From Fibrotic Mechanisms to Clinically Effective Therapeutics. \nNow in its 4th year\, the digital AFDD summit is the industry’s definitive guide to turning mechanistic understanding of fibrosis into clinically effective therapeutics across disease areas. With 3 days of in-depth cutting-edge case studies and the highest calibre of discussions from cross-disciplinary fibrosis heavy-weights\, AFDD will bridge the current translational gap to anti-fibrotic drug development success \nJoin 100+ fibrosis experts at this fully digital event to build a comprehensive network with like-minded peers and hurdle your translational drug development challenges to accelerate the development of more clinically effective drugs. \nTo know more about 4th Annual Antifibrotic Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-annual-antifibrotic-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T044308
CREATED:20201021T154020Z
LAST-MODIFIED:20201022T115845Z
UID:27582-1605484800-1605743999@www.pharmajournalist.com
SUMMARY:3rd Lifecycle Management for Combination Products Summit
DESCRIPTION:The 3rd Lifecycle Management for Combination Products Summit is the only dedicated meeting focusing on Lifecycle Management (LCM) and perfecting design control. This year the meeting will unite senior combination products leaders online to discuss strategies and lessons learned to help you ensure commercial competitiveness in the combination product markets. From quality and product development\, to CMC and regulatory affairs\, our experts speakers will help you delve into how to produce a quality and safe combination product\, implications of EU MDR and the final implementation phase of post-market surveillance reporting. \nTo know more about 3rd Lifecycle Management for Combination Products Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-lifecycle-management-for-combination-products-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201119
DTSTAMP:20260515T044308
CREATED:20200910T131817Z
LAST-MODIFIED:20200917T152111Z
UID:26980-1605571200-1605743999@www.pharmajournalist.com
SUMMARY:Clinical Operations in Oncology Trials USA 2020: Virtual Conference
DESCRIPTION:As the industry grapples with unprecedented challenges\, join us for our first ever Clinical Operations in Oncology Trials USA Virtual Experience brought to you directly in the comfort of your home! Bringing together experts from across the country to discuss the latest innovations in technology\, regulatory affairs as well as discover new opportunities through adaptive approaches and methods to run successful clinical trials.\n\nTo know more about Clinical Operations in Oncology Trials USA 2020 please click here.
URL:https://www.pharmajournalist.com/event/clinical-operations-in-oncology-trials-usa-2020-virtual-conference/
LOCATION:Virtual Event\, CA
ORGANIZER;CN="Arena International Events Group":MAILTO:alex.fearn@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201117
DTEND;VALUE=DATE:20201120
DTSTAMP:20260515T044308
CREATED:20200923T134148Z
LAST-MODIFIED:20200923T134148Z
UID:27221-1605571200-1605830399@www.pharmajournalist.com
SUMMARY:CRISPR 2.0
DESCRIPTION:Discover the Next Generation of CRISPR Tools to Enhance Specificity\, Reduce Off-Target Effects & Transform Gene Editing into a Clinical Reality \nCRISPR is one of the most powerful discoveries of the last decade. \nIn a remarkably short space of time\, ‘classic’ CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox\, which leads to the question: what’s next? \nCRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology\, from the potential of prime editing through to epigenome editing to treat chronic pain. \nDon’t get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools. \nJoin us to usher in the next generation of safe\, targeted and effective genome editing. \nFor more information on the conference\, visit https://ter.li/ok8ifs \n“Thank you for having me. I have attended all CRISPR Congresses and they keep getting better” John Sundman\, Past attendee\, CRISPR Event Series \n” I greatly enjoyed the diversity and topic coverage of the talks\, thanks for putting together an excellent program!” Christina Kolodzy\, Past attendee\, CRISPR Event Series \n “A high-quality worthwhile conference\, attended by first rate professionals. I learned more than I anticipated I would” Past attendee\, CRISPR Event Series
URL:https://www.pharmajournalist.com/event/crispr-2-0/
LOCATION:Digital Congress
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T044308
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
END:VCALENDAR